Recursion Pharma (NASDAQ: RXRX) up 78% - sell shovels in gold rushes

Recursion Pharmaceuticals (NASDAQ: RXRX) stock is up 78%. RXRX stock jumped on the news that Nvidia (NASDAQ: NVDA) had made a $50 million investment in the company. Given the size of Recurstion, a $1.3 billion market capitalisation, a near half billion cash pile, this is not transformative purely on financial grounds. It does, however, provide a guide to how the company is thinking about this new world of AI and so on.

 Recursion does develop drugs: “Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation;” and so on. But rather more importantly Recursion has developed the AI tools to be able to search for drugs that could and should be developed.

 It then becomes a strategic decision. Which is more important? Using the tools to develop drugs? Or hiring out, selling on, the tools for other to develop drugs from? Which is better will depend upon a calculation of how many drugs can be developed individually as against how many customers can be signed up for the tools - and the terms upon which the tools can be charged for.

  Recursion Pharmaceuticals stock price from NASDAQ

 The vibe we're getting from the Nvidia deal is the idea that it's the tools that are uppermost in management minds. “Chipmaker Nvidia  will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery, the companies said Wednesday.” If there is this new method of drug discovery, this AI method, then perhaps profits will be maximised not by trying to develop drugs in house, but by spitting out the drug targets from the AI and then allowing, encouraging, others to develop them? 

 Essentially this comes down to the old gold rush thought. When there's a gold rush on do you want to be one of the gold miners? Sure you do - if you're the one that finds the gold mine. On the other hand the folk selling the shovels get a piece of the action from every gold claim and stake, even those that come up empty. Century long fortunes have been made by being the suppliers - Levi Strauss really started out clothing the 49er miners.

 Now, whether in the end this works is something that we'll, well, we'll find out in the end. But selling the AI tools, or even the results of the AI models, will definitely produce cashflow much earlier than trying to develop drugs directly. Given the time value of money this may well be fiscally optimal therefore.